** ASX-listed shares of inflammatory disease drug maker Mesoblast MSB.AX rise as much as 2.3% to A$2.465, their biggest intra-day percentage gain since October 21

** MSB says co will meet with U.S. Food & Drug Administration in early December to discuss data on opioid reduction

** Says co will also discuss cessation from its first Phase 3 study (MSB-DR003) of rexlemestrocel-L in patients with chronic low back pain

** Stock third-biggest percentage gainer in the S&P/ASX 200 Health care sub-index

** Stock currently up 1% at A$2.435

** Stock down 22.3% this year, including the day's move

(Reporting by Roushni Nair in Bengaluru)

((Roushni.nair@thomsonreuters.com))